NADPH oxidase has been identified as a major contributor to disease pathology in several neurologic conditions, including amyotrophic lateral sclerosis, Alzheimer’s disease, and Parkinson’s disease. Here, FMO5 is linked to early-onset autosomal dominant Alzheimer disease.